VIVEbiotech Strengthens Its In Vivo Capabilities
New batches in production and active participation in 12 programs, driving innovation in gene therapy.
VIVEbiotech is proud to announce a major milestone in our in vivo track record. This year, we are manufacturing new batches that reinforce our leadership in in vivo applications.
We are currently involved in 12 programs, including some that are already treating patients. With 10 years of experience and collaborations with 50 international clients across the US, Europe, Australia, and Asia, VIVEbiotech continues to lead in lentiviral vector manufacturing for both ex vivo and in vivo therapies.
We look forward to supporting new partners and advancing innovative therapies together.
📩 Get in touch to discuss how we can adapt to your specific requirements: vivebiotech.com
▶ Watch the full video here.